Brii Biosciences Limited · HKEX:2137
Brii Biosciences — Investor Presentation (May 2025)
27 slides from Brii Biosciences's investor presentation, May 2025
Slide 1: Corporate Presentation
Stock Code: 2137.HK Corporate Presentation MAY 2025
Slide 2: Disclaimer
Disclaimer This presentation has been delivered for information purposes only and upon the express understanding that recipients of this presentation will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase sec
Slide 3: Who We Are
Who We Are Our Mission Our Focus Tackle public health challenges through Novel treatment options for HBV cure and breakthrough scientific innovation and areas of high unmet need within infectious critical patient insights diseases High unmet Patients experience Limited medical needs disease-related
Slide 4: World-class Leadership Team with a Proven Track Record of Success
World-class Leadership Team with a Proven Track Record of Success Corporate Executive Team Eleanor (Ellee) de Groot Zhi Hong Brian A. Johns Ankang Li Chief Technology Officer Chief Executive Officer Chief Scientific Officer Chief Strategy & Financial Officer Former EVP of Operations at Alaunos Forme
Slide 5: World-class Leadership Team with a Proven Track Record of Success
World-class Leadership Team with a Proven Track Record of Success Board of Directors Zhi Hong Ankang Li Martin J. Murphy, Jr. Grace Hui Tang Yiu Wa Alec Tsui Gregg Huber Alton Taiyin Yang Executive Director Executive Director Independent Independent Independent Independent Independent Non-executive
Slide 6: Infectious Diseases Pipeline
Infectious Diseases Pipeline Brii Indication Program Pre-clinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Commercial Partners Rights BRII-179 Global - Greater HBV Curative Treatments(1) Elebsiran(2) China(4) Greater Tobevibart(3) China(4) BRII-732 Global - HIV Long-Acting BRII-753 Global - MDR/XDR Gram-
Slide 7: HBV: Road to Cure
HBV Road to Cure
Slide 8: China is the Largest Market for HBV Functional Cure
China is the Largest Market for HBV Functional Cure Large Addressable Patient Population High Unmet Need for New Therapy Options No new novel MoAs have been approved in over 20 years Number of HBV USD expected for the ~254M Infected People ~3.4B China HBV market by Current SOC consisting of NRTIs or
Slide 9: The Natural History of Chronic HBV Infection is Complex
The Natural History of Chronic HBV Infection is Complex Leaving HBV Patients at Different Stages of Disease and Underlying Immune Impairment Active hepatitis, reactivation and hepatitis flares significantly increase the risk of developing cirrhosis and hepatocellular carcinoma (HCC) HBeAg+ HBeAg- an
Slide 10: Novel Combination Therapies May Lead to Higher Functional Cure Rates
Novel Combination Therapies May Lead to Higher Functional Cure Rates Across All HBV Patient Groups Antiviral and immunomodulation are critical targets for successful HBV therapy Reduction of viral antigen / genomic products Goal of New Therapies – HBV Functional Cure: ✓ Sustained, undetectable serum
Slide 11: Brii Bio's Programs for HBV Functional Cure Focus on Unique Mechanisms of Action
Brii Bio’s Programs for HBV Functional Cure Focus on Unique Mechanisms of Action for Both Host and Viral Pathways BRII-179 Host Pathways Innate Immune Responses Adaptive Immune Responses Optimized Recombinant Virus-like Particle (VLP)-Based Vaccine NK Cells, other Innate B Cells, CD4+, Immune Cells
Slide 12: Brii Bio's HBV Functional Cure Program Overview
Brii Bio’s HBV Functional Cure Program Overview Multiple Completed and Ongoing Phase 2 Combination Studies Completed Clinical Trials Phase 1 Phase 2 Phase 3 Elebsiran + BRII-179 BRII-179 + PEG-IFNα Ongoing Clinical Trials Phase 1 Phase 2 Phase 3 ENSURE (elebsiran + PEG-IFNα vs PEG-IFNα) ENRICH (BRII
Slide 13: Therapeutic Vaccine BRII-179 Induced Strong Anti-HBs Antibody Responses
64001-003 65001-001 66002-002 66001-001 Therapeutic Vaccine BRII-179 Induced Strong Anti-HBs Antibody Responses 66003-001 82001-001 82002-001 82003-002 Associated with Pre-S1/S2-Specific CD4 T-cell Responses 82003-003 85201-002 85203-001 85203-003 85203-004 88605-001 Anti-HBs production is associate
Slide 14: Scientific Insights from Prior Studies: Patient Enrichment via BRII-179 Immune Profiling
Scientific Insights from Prior Studies: Patient Enrichment via BRII-179 Immune Profiling BRII-179 may identify a Immune capable patients Higher functional cure rate proportion of patients who are identified by BRII-179 achieved in anti-HBs can better respond to a induced anti-HBs; these responder cu
Slide 15: Multiple Ongoing HBV Phase 2b Studies Will Inform Optimized Regimens
Multiple Ongoing HBV Phase 2b Studies Will Inform Optimized Regimens for Regulatory Approval ENSURE ENRICH ENHANCE Elebsiran + PEG-IFNα vs BRII-179→ Elebsiran BRII-179 + Elebsiran PEG-IFNα + PEG-IFNα + PEG-IFNα Head-to-head comparisons to A sequential combination study A concurrent combination study
Slide 16: ENSURE Study: Elebsiran's Added Benefits Over PEG-IFN Alone
ENSURE Study: Elebsiran’s Added Benefits Over PEG-IFN Alone and BRII-179’s Unique Value Proposition in Patient Immune Profiling for Cure Time point of data cut STUDY WEEK 00 04 08 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 NRTl Treatment Cohorts 1-3 PEG-IFNα QW Follow Up BRII-179 naïve with ba
Slide 17: ENRICH Study: Potential Curative Treatment Paradigm
ENRICH Study: Potential Curative Treatment Paradigm - Selecting Patients and Optimizing Functional Cure Outcomes Goal to enrich CHB patients capable of a higher rate of functional cure, while minimizing treatment in those less likely to achieve curative outcome BRII-179 Immunologic First Phase Primi
Slide 18: ENHANCE Study: A Controlled Concurrent Combination Study
ENHANCE Study: A Controlled Concurrent Combination Study Evaluating BRII-179, Elebsiran and PEG-IFN for Maximum Curative Outcome Phase 2a Elebsiran/BRII-179 vs Elebsiran Study Phase 2a BRII-179/PEG-IFNα vs PEG-IFNα Study ➢ Elebsiran alone reduced HBsAg level but did not ➢ BRII-179/ PEG-IFNα had mor
Slide 19: Upcoming Data Readout Timeline
Upcoming Data Readout Timeline ✓ ENSURE study Cohort 4: 48-week end of treatment announced at EASL 2025 2025 H1 ✓ ENSURE study Cohorts 1-3: 24-week follow-up announced at EASL 2025 2025 H2 ❑ ENSURE study Cohort 4: 24-week follow-up 2026 H1 ❑ ENRICH study: end of treatment 19
Slide 20: HIV: Long-Acting Treatment Options
HIV Long-Acting Treatment Options
Slide 21: Daily Oral Market Expected to Shift to Long-Acting Options
Daily Oral Market Expected to Shift to Long-Acting Options as New Therapies Become Available Global Market Will Continue to Increase High Unmet Need for Long-Acting Therapy Options • Global HIV market reached $37.6 billion in 2020 • Developed markets, such as the United States, currently Patient Sur
Slide 22: Brii Bio is Developing a Long-Acting Injectable and Oral Formulations of EFdA Prodrug
Brii Bio is Developing a Long-Acting Injectable and Oral Formulations of EFdA Prodrug to be Combined with Other MoAs Building a Long-Acting HIV Therapy Portfolio NRTI: nucleoside reverse transcriptase inhibitor • BRII-753 is an injectable NCE in the BRII-753/732 NRTTI: nucleoside reverse transcripta
Slide 23: BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies
BRII-753 and BRII-732 are Ideal Cornerstones for Next Generation HIV Therapies Ideal Backbone for Once Weekly & Long-Acting Injectable Combinations: Capsid Inhibitor 3 2 1 OR BRII-753 MoAs Drugs Injection or + NNRTI OR Integrase Inhibitor NRTI, BRII-732/753, or Tablet Long- Acting BRII-732 OR NRTTI,
Slide 24: Antibiotic Resistance
Antibiotic Resistance Mitigating a Major Public Health Threat
Slide 25: Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need
Increasing Antibiotic Resistance Drives a Critical Unmet Clinical Need WHO Priority #1 List for New Drugs Unmet Needs for Gram-Negative Bacterial Infections Indication Program Modality Positioning MDR/XDR gram- Safer and Best- negative BRII-693 IV Polymyxin In-Class Hospital bacterial infections Ant
Slide 26: BRII-693 is a Potent and Safer New-Generation Polymyxin
BRII-693 is a Potent and Safer New-Generation Polymyxin Very limited choices of antibiotics to treat carbapenem-resistant Acinetobacter spp. and P. aeruginosa, particularly for critical ill patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia Polymyxin B o
Slide 27: Thank You!
Stock Code: 2137.HK Thank You!